PROKIDNEY CORP.

Listed Company

PROKCIK 0001850270NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)E9FY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-68.99M

Total Assets

$335.57M

Equity

$-1.01B

Shares Out

—

Op. Cash Flow

$-120.12M

Business

ProKidney Corp. is a clinical-stage biotechnology company developing autologous cell therapies to preserve kidney function in chronic kidney disease (CKD). Its primary product candidate is rilparencel, a personalized formulation of Selected Renal Cells (SRC) grown from a patient’s own kidney biopsy and delivered by minimally invasive, image-guided percutaneous injections. Key business activities include clinical development (Phase 2 and Phase 3 trials), proprietary manufacturing and quality control operations, and research and development of additional kidney-focused cell therapy candidates. The company conducts clinical trials and distributes investigational product through clinical sites in the United States, Latin America, Asia Pacific and other international centers, and operates internal cGMP-aligned manufacturing for trial and potential commercial supply.

Summary from filing dated 2025-03-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	893,000	76,000	0	0	—
Research and development	114	128	107	82	46
General and administrative	52	56	45	71	9
Total operating expenses	166	184	152	153	55
Operating loss	−165	−184	−152	−153	−55
Interest income	14	20	22	6	2,000
Interest expense	−4,000	−9,000	−12,000	−215,000	0
Net loss before income taxes	−151	−164	−129	−147	−55
Income tax (benefit) expense	414,000	−598,000	6	896,000	38,000
Net loss before noncontrolling interest	−152	−163	−135	−148	−55
Net loss attributable to noncontrolling interest	−83	−102	−100	−40	0
Net loss available to Class A ordinary shareholders	−69	−61	−35	—	−55

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	109	99	61	490	21
Marketable securities	161	259	302	0	—
Interest receivable	1	2	1	0	—
Prepaid assets	3	4	3	3	588,000
Prepaid clinical	4	12	6	10	6
Assets held for sale	0	19	0	—	—
Other current assets	3	80,000	9,000	1	25,000
Total Current Assets	281	396	374	505	27
Fixed assets, net	51	42	42	11	11
Right of use assets, net	4	3	4	2	1
Total assets	336	441	421	518	40
Accounts payable	940,000	4	5	3	3
Lease liabilities	1	765,000	803,000	493,000	267,000
Accrued expenses and other	29	31	18	7	9
Income taxes payable	0	682,000	1	0	—
Total current liabilities	31	36	25	11	12
Income tax payable, net of current portion	1	748,000	568,000	278,000	0
Lease liabilities, net of current portion	3	2	4	2	1
Total liabilities	35	39	29	13	13
Commitments and Contingencies	—	—	—	—	—
Redeemable noncontrolling interest	1,312	1,397	1,495	1,602	0
Additional paid-in capital	259	206	36	7	0
Accumulated other comprehensive gain	56,000	130,000	130,000	0	—
Accumulated deficit	−1,270	−1,201	−1,140	−1,104	−162
Total shareholders' deficit	−1,011	−995	−1,103	−1,097	27
Total liabilities and shareholders' deficit	336	441	421	518	40

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	7	5	4	3	2
Equity-based compensation	25	29	31	74	699,000
Gain on marketable securities, net	−3	−7	−6	0	—
Gain on lease disposition	−29,000	−161,000	0	0	—
Impairment charges	318,000	5	0	0	—
Loss on disposal of equipment	1	56,000	23,000	0	0
Interest receivable	1	−1	−1	0	—
Prepaid and other assets	6	−6	5	−7	−6
Accounts payable and accrued expenses	−6	12	12	494,000	8
Income taxes payable	−356,000	−609,000	2	278,000	0
Net cash flows used in operating activities	−120	−126	−90	−77	−50
Proceeds from sale of facility	18	0	0	—	—
Purchases of marketable securities	−217	−324	−472	0	0
Sales and maturities of marketable securities	318	374	176	0	0
Purchase of equipment and facility expansion	−15	−30	−34	−2	−5
Net cash flows provided by (used in) investing activities	104	20	−330	−2	−5
Proceeds from sales of Class A ordinary shares, net of offering costs	24	144	0	0	0
Payments on finance leases	−26,000	−54,000	−52,000	−32,000	−30,000
Exercise of stock options	1	140,000	0	0	—
Net cash flows provided by (used in) financing activities	26	144	−10	549	71
Net change in cash and cash equivalents	9	38	−430	470	16
Right of use assets obtained in exchange for lease obligations	2	3	3	1	0
Exchange of Class B ordinary shares	5	15	10	—	—
Impact of equity transactions and compensation on redeemable noncontrolling interest	3	19	3	6	0
Equipment and facility expansion included in accounts payable and accrued expenses	131,000	347,000	218,000	51,000	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro